Mesoblast's positive Revascor data could expand market for heart stem cell therapy
This article was originally published in Clinica
Executive Summary
Mesoblast is set to press on with Phase IIb trials of Revascor, its cardiovascular stem cell therapy, following positive Phase IIa results.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.